Users Online: 1130
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER: REVIEW ARTICLE
Year : 2015  |  Volume : 4  |  Issue : 2  |  Page : 95-97

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer


Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 ONN, United Kingdom

Correspondence Address:
Syed Imran Ali Shah
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 ONN
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-330X.155699

Rights and Permissions

Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in "castration syndrome", a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1514    
    Printed36    
    Emailed0    
    PDF Downloaded241    
    Comments [Add]    
    Cited by others 2    

Recommend this journal